期刊文献+

他汀类药物对于心房颤动防治的研究进展 被引量:4

Progress of Statins in Prevention and Treatment of Atrial Fibrillation
下载PDF
导出
摘要 他汀类药物,即羟甲基戊二酰辅酶A还原酶抑制剂,降低血浆胆固醇和低密度脂蛋白胆固醇水平的疗效确切,目前广泛应用于降低血脂水平和对心脑血管疾病的一级和二级预防。在长期临床实践及研究中,人们逐渐发现和证实了他汀类药物具有其他多种辅助性效能,即多效性作用,其中就包括对心房颤动的防治作用。 Statins and HMG CoA reductase inhibitors,effectively reduce plasma cholesterol and low-density lipoprotein cholesterol levels.They are currently widely used in reducing blood lipid levels,and the primary and secondary prevention for cardiovascular and cerebrovascular diseases.In addition,in long-term clinical practice and research,people gradually found and confirmed that statins have a variety of other auxiliary effects and named it pleiotropic effects,including the prevention and treatment of atrial fibrillation.
作者 刘刚 张恒 LIU Gang;ZHANG Heng(Department of Cardiology,The First Affiliated Hospital of Bengbu Medical College,Bengbu 233000,Anhui,China)
出处 《心血管病学进展》 CAS 2018年第6期1068-1071,共4页 Advances in Cardiovascular Diseases
关键词 羟甲基戊二酰辅酶A还原酶抑制剂 心房颤动 他汀类药物 多效性作用 HMG-CoA reductase inhibitors Atrial fibrillation Statins Pleiotropic effects
  • 相关文献

参考文献2

二级参考文献38

  • 1中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5221
  • 2Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. Lancet,2002,360 : 7-22.
  • 3Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in ld randomised trials of statins. Lancet,2005, 366 : 1267-1278.
  • 4Smith SC Jr,Allen J,Blair SN ,et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease : 2006 update. Circulat on, 2006,113:2363-2372.
  • 5Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III:a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prey Rehabil,2009,16 : 121-137.
  • 6Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease ( PROSPER ) : a randomised controlled trial. Lancet,2002,360 : 1623-1630.
  • 7Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med,2006,355: 549-559.
  • 8Niu S, Zhao D, Zhu J, et al. The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China(BRIG) Project. American Heart Journal, 2009,157 : 709-715.
  • 9MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial[ J ]. Lancet, 2002, 360(9326) : 7-22.
  • 10Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary e- vents with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study[J]. JAMA, 1998, 279(20): 1615-1622.

共引文献63

同被引文献38

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部